
    
      Patients will have unresectable advanced, recurrent or metastatic, histologically confirmed,
      well-differentiated Grade 3 NET or poorly-differentiated NEC of the pancreas,
      gastrointestinal tract lung and unknown primary site. Thirty patients will be included in
      this trial, of which 15 will not have received prior chemotherapy (Cohort 1) and 15 will have
      received at least one prior line of chemotherapy (Cohort 2). Patient will receive 240 mg flat
      dose of nivolumab intravenously as a 30-minutes infusion and 7.4 GBq 177Lu-DOTATATE
      intravenously as a 4-hours infusion. Nivolumab will be administered at Day 1 and Day 15 of a
      28-days cycle, starting on Cycle 1 Day 1. Patients will receive the study drugs while it is
      considered to be in their best interest, 177Lu-DOTATATE being administered at a maximum of 4
      injection cycle. Treatment discontinuation criteria include, among others, progression,
      unacceptable toxicity or patient study withdrawal
    
  